质子抑制剂是否有助于新兴的高血压人口?
Rohit Tayal1, Sabina Yasmin2, Samrat Chauhan1
1Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
Pharmaceuticals (Basel, Switzerland)
|October 28, 2023
概括
长期使用质子抑制剂 (PPI) 可能会增加患高血压的风险. 这项研究探讨了将PPI与高血压等心血管问题联系在一起的机制.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学 是一个学科.
- 胃肠病学 胃肠病学
背景情况:
- 质子抑制剂 (PPI) 广泛用于胃肠道问题.
- 非处方药的可用性导致了自我治疗和长期使用的增加.
- 人们对长期使用PPI存在潜在的心血管风险存在担忧.
研究的目的:
- 调查持续使用质子抑制剂 (PPI) 与高血压之间的相关性.
- 探索PPI与高血压发展相关的潜在机制.
主要方法:
- 审查关于PPI和心血管健康的现有文献.
- 对PPI诱导高血压的潜在生物途径的分析.
主要成果:
- 长期使用PPI与高血压风险增加有关.
- 潜在的机制包括内皮功能障碍,氧化生物可用性降低和电解质失衡 (低血症,低磁血症).
- 维生素B缺乏也可能起作用.
结论:
- 持续使用PPI可能会通过各种生理障碍导致高血压.
- 建议长期使用PPI者谨慎使用,特别是那些有心血管风险因素的人.
- 需要进一步的研究才能充分阐明PPI对心血管的影响.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
595
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
595
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Antihypertensive Drugs: Direct Renin Inhibitors
650
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
650
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
674
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
674
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Antihypertensive Drugs: Vasodilators
543
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
543


